Het ILD-team van de dienst Longziekten voert onderzoek naar de ontstaansmechanismen, diagnostische hulmiddelen en behandelingen van interstitiële longziekten. Het team start zelf onderzoeken op in het UZ Gent en neemt ook deel aan internationale studies.
Studiecoördinatoren
- Marlies De Coninck
- Bénédicte Demeyere
Lopende studies
Re-spire (Liquidia) - open for inclusion Q1 2026
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Liposomal Treprostinil Inhalation Suspension (L606) in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease.
Main inclusion criteria
- WHO Group 3 PH-ILD
- Any form of ILD
- Combined pulmonary fibrosis and emphysema
- FEV1/FVC >70% (Post Bronchodilatatie)
- 6MWT: >125m
Contact
marlies.deconinck@uzgent.be, tel. 09 332 23 52
Traject studie (academisch) - open for inclusion - IPF - lung cancer - COPD
Uncovering commonalities and differences: Towards a novel framework for identifying end-of-life trajectories of older people with serious chronic illness.
Main inclusion criteria
- Patients >70 years
- COPD/lung cancer/IPF/PPF
TETON-PPF - open for inclusion (end July 2026)
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (RIN-PF-305).
Main inclusion criteria
- PPF, other than IPF (radiological evidence of pulmonary fibrosis of >10% extent on an HRCT)
- Subject has a diagnosis of PPF (other than IPF) that fulfills at least 1 of the following criteria for progression within 24 months of screening:
- Clinically significant decline in % predicted FVC based on ≥10% relative decline
- Marginal decline in % predicted FVC based on ≥5% to <10% relative decline combined with worsening of respiratory symptoms
- Marginal decline in % predicted FVC based on ≥5% to <10% relative decline combined with increasing extent of fibrotic changes on chest imaging
- Worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging
- On nintedanib of pirfenidone >90 days OR not on treatment with nintedanib or pirfenidone for ≥90 days prior to Baseline and not planning to initiate either treatment during the study.
- FVC ≥45% predicted
Contact
RIN-PF-306 device study - open for inclusion (end July 2026)
A Multinational, Uncontrolled, Usability Evaluation Study of the TD-300/A Tyvaso Inhalation Device Used in RIN-PF-305
Main inclusion criteria
- Participating in de RIN-PF-305 study
Contact
Puretech LYT-100-2025-301 (open for inclusion Q3 2026)
A Randomized, Double-Blind, Head-to-Head Phase 3 trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults With Idiopathic Pulmonary Fibrosis (SURPASS-IPF).
Main inclusion criteria
- ≥ 40 y
- Meets the diagnostic criterai of IPF ATS/ERS/JRS/ALAT 2022 guidelines
- Initials IPF diagnosis <7y
- No prior exposure to pirfenidone or LYT-100
- Definite or probable UIP on HRCT
- FVC ≥45%